Ranking Reversible Covalent Drugs: From Free Energy Perturbation to Fragment Docking

Posted on February 15, 2019 by Tina Guvench

Exploring protein-protein interactions using the Site-Identification by Ligand Competitive Saturation (SILCS) methodology

Posted on January 7, 2019 by Tina Guvench

No opportunities available

Posted on November 15, 2018December 12, 2018 by Tina Guvench

There are no job opportunities available at this time. Please check back again.

Identification of Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design

Posted on September 13, 2018 by Tina Guvench

SilcsBio, LLC Announces Issuance of US Patent with Utility in Drug Design Software

Posted on July 12, 2018July 13, 2018 by Tina Guvench

FOR IMMEDIATE RELEASE: July 12, 2018 Ken Malone SilcsBio, LLC 410.929.2305 Ken.Malone@silcsbio.com SilcsBio, LLC Announces Issuance of US Patent with Utility in Drug Design Software July 12, 2018 Baltimore, Maryland: SilcsBio, LLC (SilcsBio) announced today the issuance of a US patent covering key elements of SilcsBio’s drug design software. The SilcsBio software is broadly used[…]

Small-molecule inhibitors of ERK-mediated immediate early gene expression and proliferation of melanoma cells expressing mutated BRaf

Posted on June 1, 2018June 26, 2018 by Tina Guvench

Therapeutic targeting of GCB- and ABC-DLBCLs by rationally designed BCL6 inhibitors

Posted on June 1, 2018June 26, 2018 by Tina Guvench

Acyl-2-aminobenzimidazoles: A novel class of neuroprotective agents targeting mGluR5

Posted on June 1, 2018June 26, 2018 by Tina Guvench